ValGenesis Secures $16M Strategic Financing to Accelerate Global Expansion and AI-Driven Innovation

AI in Healthcare

Insider Brief

ValGenesis has secured up to $16M in strategic financing from Bridge Bank’s Innovation Banking Group to accelerate global expansion and AI-powered product innovation in digital validation for life sciences.
The funding supports growth of the ValGenesis Smart GxP™ platform, strategic hiring, and partner expansion across North America, Europe, and Asia-Pacific amid rising demand for compliance automation.
Backed by Morgan Stanley Expansion Capital, ValGenesis is trusted by 30 of the top 50 global life sciences firms and continues to lead the market in digitizing validation lifecycle management.

PRESS RELEASE — ValGenesis® Inc., the global leader in digital validation lifecycle management and backed by investment funds managed by Morgan Stanley Expansion Capital, announced it has secured strategic financing of up to $16 million from the Innovation Banking Group at Bridge Bank®, a division of Western Alliance Bank, Member FDIC. The Innovation Banking Group specializes in serving high-growth life sciences, technology, and innovation companies.

This financing will help fuel ValGenesis’ global expansion plans and accelerate product innovation, particularly in artificial intelligence-powered validation solutions. The funding comes at a pivotal moment for ValGenesis, which recently launched a groundbreaking AI-assisted validation program and continues to set new industry standards for digitalizing validation.

“We believe this financing reflects the strong confidence that Bridge Bank and Morgan Stanley Expansion Capital have in our vision, innovation, and execution,” said Dr. Siva Samy, CEO and Chief Product Strategist at ValGenesis. “Our AI-assisted validation platform, backed by a growing number of issued patents, is transforming how life sciences companies manage compliance and accelerate time to market. This capital allows us to rapidly scale our AI offerings and deepen our global presence.”

The new funds will also support strategic hiring, regional partner expansion, and customer success initiatives across North America, Europe, and Asia-Pacific, enabling ValGenesis to meet the surging demand for digital validation solutions in regulated industries.

“Bridge Bank is honored to serve as the banking partner for ValGenesis, an innovation-driven company that is leading the way in digitalizing validation in life sciences,” said Peter Haman, market director, in Bridge Bank’s Innovation Banking Group. “We are confident that our support will enable ValGenesis to accelerate its growth trajectory and enhance its market presence while continuing to provide exceptional value to its customers.”

ValGenesis is trusted by leading pharmaceutical, biotech, and medical device organizations to digitize and automate their validation lifecycle processes, ensuring compliance, traceability, and efficiency at scale. The company recently launched ValGenesis Smart GxP™, the first AI-enabled platform purpose-built to unify validation and process lifecycle management across life sciences organizations.

“ValGenesis has consistently delivered impressive double digit growth year over year and carved out clear market leadership in bringing innovative digital validation solutions to life sciences. We are confident that this new financing positions the company to accelerate its global expansion, deepen product innovation, and redefine industry best practices,” said Melissa Daniels, Managing Director, Morgan Stanley Expansion Capital.

About ValGenesis

ValGenesis is the creator of ValGenesis Smart GxP, the life sciences industry’s first fully integrated, cloud-based, AI-enabled platform for end-to-end product lifecycle digitalization. Trusted by 30 of the world’s top 50 life sciences companies, our platform unifies intelligent, risk-based validation and process automation in a connected ecosystem — streamlining operations, driving compliance, and reducing risk. Purpose-built for life sciences, ValGenesis empowers global organizations to improve quality of life by accelerating the delivery of consistent, safer products.

About Morgan Stanley Expansion Capital

Morgan Stanley Expansion Capital is the growth-focused private investment platform within Morgan Stanley Investment Management. Morgan Stanley Expansion Capital targets growth equity and credit investments within technology, healthcare, consumer, digital media and other high-growth sectors. For over three decades, Morgan Stanley Expansion Capital has successfully pursued growth investment opportunities and has completed investments in over 200 companies, leveraging the global brand and network of Morgan Stanley.

About BridgeBank

Bridge Bank, a division of Western Alliance Bank, Member FDIC, delivers relationship banking that puts clients at the center of everything. Founded in 2001 in Silicon Valley, Bridge Bank offers a full spectrum of tailored commercial banking solutions with specialized expertise focused on life sciences and technology and innovation companies at every stage in their life cycle, from startup to IPO and beyond. With offices in major tech hubs across the country, Bridge Bank delivers the reach, resources and market expertise that make a difference for its clients. Bridge Bank also serves the private equity and venture capital communities by providing banking solutions for portfolio companies and funds, plus banking solutions for small to mid-size businesses in the Bay Area. Bridge Bank is part of Western Alliance Bancorporation, which has more than $80 billion in assets. Major accolades include being ranked as a top U.S. bank in 2024 by American Banker and Bank Director. For more information, visit Bridge Bank.